Beyond CD19: Opportunities for Future Development of Targeted Immunotherapy in Pediatric Relapsed-Refractory Acute Leukemia.

Authors

Haneen Shalabi, George Washington University
Anne Angiolillo, George Washington UniversityFollow
Terry J Fry

Document Type

Journal Article

Publication Date

1-1-2015

Journal

Frontiers in Pediatrics

Volume

3

Inclusive Pages

80

DOI

10.3389/fped.2015.00080

Abstract

Chimeric antigen receptor (CAR) T cell therapy has been used as a targeted approach in cancer therapy. Relapsed and refractory acute leukemia in pediatrics has been difficult to treat with conventional therapy due to dose-limiting toxicities. With the recent success of CD 19 CAR in pediatric patients with B cell acute lymphoblastic leukemia (ALL), this mode of therapy has become a very attractive option for these patients with high-risk disease. In this review, we will discuss current treatment paradigms of pediatric acute leukemia and potential therapeutic targets for additional high-risk populations, including T cell ALL, AML, and infant ALL.

Comments

Reproduced with permission of Frontiers Media S.A. Frontiers in Pediatrics.

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 License.

APA Citation

Shalabi, H., Angiolillo, A., & Fry, T. J. (2015). Beyond CD19: Opportunities for Future Development of Targeted Immunotherapy in Pediatric Relapsed-Refractory Acute Leukemia. Frontiers in Pediatrics, 3, 80. http://doi.org/10.3389/fped.2015.00080

Open Access

1